The effect of Levothyroxine on reduction of Thyroid nodule's volume

Evaluation the effect of Levothyroxine on reduction of benign thyroid nodule's volume in euthyroid patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015100918858N2

Enrollment

132

Registered

2016-03-31

Start date

2014-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodule. Disorders of thyroid gland

Interventions

Intervention 1: Intervention group:Levothyroxin1 micro gr/kg daily-peroral and dose modification at lenght of survey. Intervention 2: Control group: no intervention.

Treatment - Drugs

Intervention group:Levothyroxin1 micro gr/kg daily-peroral and dose modification at lenght of survey

Control group: no intervention

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.be euthyroid; 2.non malignant nodule; 3.the age range of 18 to 65 years old. Exclusion criteria:1.treatment with levothyroxin or methimazole; 2.patients of iodine deficiency areas; 3.history of surgery on thyroid; 4.history of head and neck radiation; 5.pregnancy; 6.nodule's cystic portion>20%; 7.heart disease(IHD-arrhythmia); 8.osteoporosis; 9. more than 3 nodules in every thyroid's lobe.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Size of thyroid nodules. Timepoint: At the beginnig of the study and after 6 &12 months. Method of measurement: Ultrasonography.;Volume of thyroid nodule. Timepoint: At the beginnig of the study and after 6 &12 months. Method of measurement: Ultrasonography.	—

Secondary

Measure	Time frame
TSH. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.;Anti TPO. Timepoint: At the beginnig and the end of the study. Method of measurement: Laboratory kit.;T4. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.;T3. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.	—

Measure

Time frame

TSH. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.;Anti TPO. Timepoint: At the beginnig and the end of the study. Method of measurement: Laboratory kit.;T4. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.;T3. Timepoint: At the beginnig of the study; 3 months interval in treatment group and 6 months interval in control group. Method of measurement: Laboratory kit.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026